1008361-77-0

Basic information

• Product Name: 3-BROMO-6-IODO-2-METHYLPYRIDINE
• Synonyms: 3-BROMO-6-IODO-2-METHYLPYRIDINE
• CAS NO: 1008361-77-0
• Molecular Formula: C6H5BrIN
• Molecular Weight: 297.91907
• Mol File: 1008361-77-0.mol

Chemical Properties

• Boiling Point: 264℃
• Flash Point: 114℃
• Appearance: /
• Density: 2.171
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.21±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-6-IODO-2-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-6-IODO-2-METHYLPYRIDINE(1008361-77-0)
• EPA Substance Registry System: 3-BROMO-6-IODO-2-METHYLPYRIDINE(1008361-77-0)

Safety Data

• Hazardous Substances Data: 1008361-77-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-6-iodo-2-methylpyridine is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique structure allows for the creation of diverse and complex molecules with potential biological activities.
Used in Agrochemical Industry:
In the agrochemical industry, 3-Bromo-6-iodo-2-methylpyridine serves as a key intermediate in the synthesis of various agrochemicals, aiding in the development of effective and innovative products for agricultural applications.
Used in Organic Chemistry Research:
3-Bromo-6-iodo-2-methylpyridine is utilized as a versatile compound in organic chemistry research, enabling the exploration of new reactions and the synthesis of novel organic compounds with potential applications in various fields.

Upstream product

• 42753-71-9 5-bromo-6-methyl-pyridin-2-ylamine 
• 39919-65-8 2,5-dibromo-6-methylpyridine 

Downstream Products

• 137778-18-8 5-bromo-6-methyl-pyridine-2-carbaldehyde 
• 1173897-86-3 5-bromo-6-methylpyridine-2-carbonitrile 
• 1228013-15-7 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one 

Relevant articles and documents

Povarov reaction, scope and limitations: Preparation of diversely heterocyclic tetrahydro-1H-cyclopenta[c]quinolines

Parallel synthesis of diverse heterocyclic-tetrahydro-1H-cyclopenta[c]quinolines in excellent yields and high endo diastereoselectivity has been described hereia These compounds are highly functionalized natural product-like tricyclic systems, which may be useful as biologically relevant targets. Fine tuning of the reaction conditions need to be performed depending on the nature and molecular structure of the heterocyclic aromatic carbaldehyde, as well as the choice of the Lewis acid catalyst. Synthesis of the heterocyclic aromatic aldehyde precursors of the Povarov Reaction is also described.

7A-AMIDE SUBSTITUTED-6,6-DIFLUORO BICYCLIC HIMBACINE DERIVATIVES

The present invention relates to bicyclic himbacine derivatives of the formula (structurally represented) or a pharmaceutically acceptable salt thereof wherein: R1 is -[C(Ra)(Rb)]x-[C(Rb)(Rb)]y-C(0)NH2, or -N(H)-[(CH2)]zC(0)-NH2; W is any of the recited c

PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE

Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EPl receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EPl receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EPl receptor as well as to pharmaceutical compositions comprising them.

SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS

The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.